For a brighter future...
US Pharmaceutical firm, Raptor, have successfully raised funds via a share issue to fund the next stage of trials for their new Cystinosis treatment.
DR Cysteamine is the first drug from Raptor, and it is hoped that its slow release mechanism will allow Cystinotics to take their medication only twice a day, rather than the current four times a day. The new funding will allow Raptor to continue their operations until the end of 2011, by which time they hope to have completed trials and submitted the drug for release within the USA. The trial will involve approximately 30 Cystinotics in the USA and we look forward to hearing the results.
